2024
Vascular endothelial cells derived from transgene-free pig induced pluripotent stem cells for vascular tissue engineering
Batty L, Park J, Qin L, Riaz M, Lin Y, Xu Z, Gao X, Li X, Lopez C, Zhang W, Hoareau M, Fallon M, Huang Y, Luo H, Luo J, Ménoret S, Li P, Jiang Z, Smith P, Sachs D, Tellides G, Anegon I, Pober J, Liu P, Qyang Y. Vascular endothelial cells derived from transgene-free pig induced pluripotent stem cells for vascular tissue engineering. Acta Biomaterialia 2024, 193: 171-184. PMID: 39681154, DOI: 10.1016/j.actbio.2024.12.033.Peer-Reviewed Original ResearchThis study created transgene-free pig induced pluripotent stem cells for engineered blood vessels that prevent clots, opening new possibilities for modeling improved cardiovascular treatments.
2016
Nucleoside reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signaling in endothelial cells.
Song L, Zhu X, Qiu C, Qin L, Chow S, Yu L. Nucleoside reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signaling in endothelial cells. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.300.2.Peer-Reviewed Original ResearchAntiretroviral therapyReceptor tyrosine kinasesEndothelial cellsRole of ARTEndothelial mitochondrial dysfunctionHIV-positive patientsMicrovascular endothelial cellsVascular endothelial cellsAortic endothelial cellsNRTI treatmentTyrosine kinaseBlood vessel growthMicrovascular functionImmunodeficiency syndromeInhibitor administrationKaposi's sarcomaClinical challengeNoncommunicable diseasesNRTIsNotch1 pathwayAngiogenic pathwaysLymphangiogenic functionTumor angiogenesisLymphatic endothelial cellsReceptor signaling
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply